Etanercept is a fully human, soluble tumour necrosis factor (TNF)–receptor fusion protein that is approved to treat moderate to severe plaque psoriasis at a dosage of 50 mg twice weekly for up to 3 months, followed by 50 mg once weekly.8,9 Etanercept has been shown to improve disease symptoms and health-related quality of life while maintaining an acceptable safety and tolerability profile in patients with moderate to severe plaque psoriasis.10–16. Here, TNF is linked to psoriasis vulgaris.